Restricted accessLetterFirst published online 2026
Letter to the Editor: Indication-Specific Cost-Effectiveness of Empagliflozin Versus Dapagliflozin: Implications for Clinical and Policy Decision-Making
ZhengPPZhaoYNDuM, et al. Comparative effectiveness of empagliflozin and dapagliflozin in Chinese patients with Type 2 diabetes mellitus. Hosp Pharm. Published online December 12, 2025. doi:10.1177/00185787251392803
2.
GourzoulidisGTzanetakosCIoannidisI, et al. Cost-effectiveness of empagliflozin compared with dapagliflozin for the treatment of patients with type 2 diabetes mellitus and established cardiovascular disease in Greece. Clin Drug Investig. 2021;41(4):371-380. doi:10.1007/s40261-021-01013-w
3.
ReifsniderOSKansalARGandhiPK, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care. 2021;9(1):e001313. doi:10.1136/bmjdrc-2020-001313
4.
ZhangHChenJZhaoQZhangB.Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China. Front Public Health. 2025;13:1566101. doi:10.3389/fpubh.2025.1566101
5.
DarvishiADaroudiRDehghanSHeshmatRShafieeG.Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2. Sci Rep. 2025;15(1):41536. doi:10.1038/s41598-025-25456-9
6.
CohenLPIsazaNHernandezI, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction. JAMA Cardiol. 2023;8(5):419-428. doi:10.1001/jamacardio.2023.0077
7.
NechiRNRaneAKarayeRM, et al. Cost-Effectiveness of dapagliflozin vs empagliflozin for treating heart failure with reduced ejection fraction in the United States. Clin Ther. 2023;45(7):627-632. doi:10.1016/j.clinthera.2023.05.002
8.
JiangYZhengRSangH.Cost-effectiveness of adding SGLT2 inhibitors to standard treatment for heart failure with reduced ejection fraction patients in China. Front Pharmacol. 2021;12:733681. doi:10.3389/fphar.2021.733681
9.
KongmalaiTPrawjaengJHadnorntunP, et al. Cost-utility and budget impact analysis of adding SGLT-2 inhibitors to standard treatment in Type 2 diabetes patients with heart failure: utilizing national database insights from Thailand. Pharmacoecon Open. 2025;9(1):69-81. doi:10.1007/s41669-024-00526-2
10.
NguyenBNMitalSBugdenSNguyenHV.Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. Int J Cardiol. 2023;376:83-89. doi:10.1016/j.ijcard.2023.01.080
11.
RaneANechiRNImamM, et al. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2023;29(9):1045-1053. doi:10.18553/jmcp.2023.29.9.1045
12.
LuHShangPZhouD.SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study. Front Pharmacol. 2023;14:1155210. doi:10.3389/fphar.2023.1155210
13.
QiuTLiPYanD.Cost-Effectiveness of adding dapagliflozin and empagliflozin to standard treatment for diabetic kidney disease in China. Clin Drug Investig. 2025;45(9):651-664. doi:10.1007/s40261-025-01462-7
14.
ChitpimNLeelahavarongPPrawjaengJIttiphisitSSrinonprasertVKongmalaiT.A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand. Sci Rep. 2025;15(1):249. doi:10.1038/s41598-024-81747-7
